DC Circ. Signs Off On Serial Exclusivity For Orphan Drugs
Multiple drug manufacturers are entitled to marketing exclusivity once they designate a drug as an orphan, the D.C. Circuit ruled Friday, backing Eagle Pharmaceuticals' win in the U.S. Food and Drug...To view the full article, register now.
Already a subscriber? Click here to view full article